Therapeutic advances in medical oncology

Keyphrases

Publications

volume 16, 2024

Jian Cui, Tengteng Yu, Rui Lv, Jiahui Liu, Huishou Fan, Wenqiang Yan, Jingyu Xu, Chenxing Du, Shuhui Deng, Weiwei Sui, Matthew Ho, Yan Xu, Kenneth C Anderson, Xifeng Dong, Lugui Qiu, Gang An
Longitudinal genetically detectable minimal residual disease by fluorescence in situ hybridization confers a poor prognosis in myeloma. Therapeutic advances in medical oncology 16 (2024)
Junli Xue, Liqiong Xue, Wenbo Tang, Xiaoxiao Ge, Wei Zhao, Qun Li, Wei Peng, Congqi Dai, Ye Guo, Jin Li
TQB2450 in patients with advanced malignant tumors: results from a phase I dose-escalation and expansion study. Therapeutic advances in medical oncology 16 (2024)
Xiaolei Liu, Ruiquan Zhou, Liguo Liu, Shuang Si, Shiwei Yang, Dongdong Han, Haidong Tan
Short-term outcomes of combined therapy with sirolimus and interferon-alpha 2b for advanced hepatic epithelioid hemangioendothelioma. Therapeutic advances in medical oncology 16 (2024)
Chih-Hao Chang, Shih-Hao Huang, Hung-Yu Huang, Meng-Hung Lin, Chung-Shu Lee, Hsin-Fu Lee, Jason Chia-Hsun Hsieh, Chun-Yu Cheng
Major adverse cardiovascular events in advanced-stage lung cancer: a multicenter cohort study. Therapeutic advances in medical oncology 16 (2024)
XinYi Hong, ShanHu Qiu, Bo Ding, Hao Xu, Yang Shen
Combined use of Anlotinib with chemotherapy in patients with advanced ovarian cancer: a real-world cohort study and meta-analysis. Therapeutic advances in medical oncology 16 (2024)
Hong Yuan, Fei Xu, Shengzhou Wang, Di Liu, Huan Zhang, Jun Zhang, Min Shi, Chao Yan, Zhenggang Zhu
Analysis of circulating tumor DNA identifies distinct therapeutic response to intraperitoneal and intravenous paclitaxel plus S-1 in gastric cancer patients with peritoneal metastasis. Therapeutic advances in medical oncology 16 (2024)
Jaime Carrillo-García, Serena Lacerenza, Nadia Hindi, Irene Carrasco García, Gloria Marquina, Juana María Cano Cano, Javier Martínez Trufero, Alberto Rafael Sevillano Tripero, Tania Luis García, Manuel Jorge Cuesta Rioboo, David S Moura, Marta Renshaw, Jose L Mondaza-Hernandez, Davide Di Lernia, Antonio Gutierrez, Javier Martín-Broto
Delays in diagnosis and surgery of sarcoma patients during the COVID-19 outbreak in Spain. Therapeutic advances in medical oncology 16 (2024)
Maria Teresa Bourlon, Paola Valdez, Elena Castro
Development of PARP inhibitors in advanced prostate cancer. Therapeutic advances in medical oncology 16 (2024)
Kaiqi Lan, Jingrong Mao, Xuesong Sun, Suchen Li, Siyi Xie, Rui Sun, Sailan Liu, Hai-Qiang Mai
Combined pre-treatment and middle-treatment Epstein-Barr virus DNA load contributes to prognostication and treatment modification in nasopharyngeal carcinoma patients. Therapeutic advances in medical oncology 16 (2024)
Xiaolei Liu, Ruiquan Zhou, Liguo Liu, Shuang Si, Shiwei Yang, Dongdong Han, Haidong Tan
Short-term outcomes of combined therapy with sirolimus and interferon-alpha 2b for advanced hepatic epithelioid hemangioendothelioma. Therapeutic advances in medical oncology 16 (2024)
Pi-Hung Tung, Tzu-Hsuan Chiu, Allen Chung-Cheng Huang, Jia-Shiuan Ju, Chi-Hsien Huang, Chin-Chou Wang, How-Wen Ko, Fu-Tsai Chung, Ping-Chih Hsu, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Yang
Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC. Therapeutic advances in medical oncology 16 (2024)
Kaiqi Lan, Jingrong Mao, Xuesong Sun, Suchen Li, Siyi Xie, Rui Sun, Sailan Liu, Hai-Qiang Mai
Combined pre-treatment and middle-treatment Epstein-Barr virus DNA load contributes to prognostication and treatment modification in nasopharyngeal carcinoma patients. Therapeutic advances in medical oncology 16 (2024)
Pei Yuan, Xuemin Xue, Tian Qiu, Jianming Ying
MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature. Therapeutic advances in medical oncology 16 (2024)
Teng Ma, Changgen Liu, Tianyi Ma, Xinyi Sun, Jian Cui, Lulu Wang, Yan Mao, Haibo Wang
The impact of the HER2-low status on conditional survival in patients with breast cancer. Therapeutic advances in medical oncology 16 (2024)
Bruno Vincenzi, Alessio Cortellini, Alessandro Mazzocca, Sarah Orlando, Davide Romandini, Juan Aguilar, Isabel Ruiz-Camps, Claudia Valverde Morales, Simeon Eremiev-Eremiev, Carlo Tondini, Joan Brunet, Rossella Bertulli, Salvatore Provenzano, Mark Bower, Daniele Generali, Ramon Salazar, Anna Sureda, Aleix Prat, Michalarea Vasiliki, Mieke Van Hemelrijck, Ailsa Sita-Lumsden, Alexia Bertuzzi, Sabrina Rossi, Amanda Jackson, Federica Grosso, Alvin J X Lee, Cian Murphy, Katherine Belessiotis, Uma Mukherjee, Fanny Pommeret, Angela Loizidou, Gianluca Gaidano, Gino M Dettorre, Salvatore Grisanti, Marco Tucci, Claudia A M Fulgenzi, Alessandra Gennari, Andrea Napolitano, David J Pinato
Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry. Therapeutic advances in medical oncology 16 (2024)
Jaime Carrillo-García, Serena Lacerenza, Nadia Hindi, Irene Carrasco García, Gloria Marquina, Juana María Cano Cano, Javier Martínez Trufero, Alberto Rafael Sevillano Tripero, Tania Luis García, Manuel Jorge Cuesta Rioboo, David S Moura, Marta Renshaw, Jose L Mondaza-Hernandez, Davide Di Lernia, Antonio Gutierrez, Javier Martín-Broto
Delays in diagnosis and surgery of sarcoma patients during the COVID-19 outbreak in Spain. Therapeutic advances in medical oncology 16 (2024)
Maria Teresa Bourlon, Paola Valdez, Elena Castro
Development of PARP inhibitors in advanced prostate cancer. Therapeutic advances in medical oncology 16 (2024)
Baptiste Cervantes, Thierry André, Romain Cohen
Deficient mismatch repair/microsatellite unstable colorectal cancer: therapeutic advances and questions. Therapeutic advances in medical oncology 16 (2024)
Noémie Huchet, Nicolas Penel, Sylvie Bonvalot, Juliette Thariat, Françoise Ducimetière, Antoine Giraud, Maud Toulmonde, Axel Le Cesne, Jean-Yves Blay, Jean-Yves Blay
Handling missing covariates in observational studies: an illustration with the assessment of prognostic factors of survival outcomes in soft-tissue or visceral sarcomas in irradiated fields (SIF). Therapeutic advances in medical oncology 16 (2024)
Yohei Kubota, Kohei Shitara
Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer. Therapeutic advances in medical oncology 16 (2024)
Yuehua Liang, Xiaoran Liu, Zehui Yun, Kun Li, Huiping Li
Endocrine therapy plus HER2-targeted therapy, another favorable option for HR+/HER2+ advanced breast cancer patients. Therapeutic advances in medical oncology 16 (2024)
Yuehua Liang, Xiaoran Liu, Zehui Yun, Kun Li, Huiping Li
Endocrine therapy plus HER2-targeted therapy, another favorable option for HR+/HER2+ advanced breast cancer patients. Therapeutic advances in medical oncology 16 (2024)
XinYi Hong, ShanHu Qiu, Bo Ding, Hao Xu, Yang Shen
Combined use of Anlotinib with chemotherapy in patients with advanced ovarian cancer: a real-world cohort study and meta-analysis. Therapeutic advances in medical oncology 16 (2024)
Qianming Bai, Xiaohua Shi, Xiao-Yan Zhou, Zhiyong Liang, Shun Lu, Yilong Wu
Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer. Therapeutic advances in medical oncology 16 (2024)
Jian Pan, Tingwei Zhang, Shouzhen Chen, Ting Bu, Jinou Zhao, Xudong Ni, Benkang Shi, Hualei Gan, Yu Wei, Qifeng Wang, Beihe Wang, Junlong Wu, Shaoli Song, Feng Wang, Chang Liu, Dingwei Ye, Yao Zhu
Nomogram to predict the presence of PSMA-negative but FDG-positive lesion in castration-resistant prostate cancer: a multicenter cohort study. Therapeutic advances in medical oncology 16 (2024)
Noémie Huchet, Nicolas Penel, Sylvie Bonvalot, Juliette Thariat, Françoise Ducimetière, Antoine Giraud, Maud Toulmonde, Axel Le Cesne, Jean-Yves Blay, Jean-Yves Blay
Handling missing covariates in observational studies: an illustration with the assessment of prognostic factors of survival outcomes in soft-tissue or visceral sarcomas in irradiated fields (SIF). Therapeutic advances in medical oncology 16 (2024)
Yohei Kubota, Kohei Shitara
Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer. Therapeutic advances in medical oncology 16 (2024)
Jian Cui, Tengteng Yu, Rui Lv, Jiahui Liu, Huishou Fan, Wenqiang Yan, Jingyu Xu, Chenxing Du, Shuhui Deng, Weiwei Sui, Matthew Ho, Yan Xu, Kenneth C Anderson, Xifeng Dong, Lugui Qiu, Gang An
Longitudinal genetically detectable minimal residual disease by fluorescence in situ hybridization confers a poor prognosis in myeloma. Therapeutic advances in medical oncology 16 (2024)
Jin Ho Choi, Hwanhee Park, Joo Kyung Park, Jong Kyun Lee, Kyu Taek Lee, Kwang Hyuck Lee
Prolonged progression-free survival achieved by gemcitabine, cisplatin, and albumin-bound paclitaxel for the treatment of advanced biliary tract cancers. Therapeutic advances in medical oncology 16 (2024)
István Farkas, Gábor Sipka, Annamária Bakos, Anikó Maráz, Zoltán Bajory, Zsófia Mikó, Tamás Czékus, Szabolcs Urbán, Linda Varga, László Pávics, Zsuzsanna Besenyi
Diagnostic value of [ 99m Tc]Tc-PSMA-I&S-SPECT/CT for the primary staging and restaging of prostate cancer. Therapeutic advances in medical oncology 16 (2024)
Kimberly M Burcher, Chance H Bloomer, Elena Gavrila, John M Kalada, Mark J Chang, Rediet R Gebeyehu, Alexander H Song, Lara M Khoury, Thomas W Lycan, Rebecca Kinney, Ralph D'Agostino, Paul M Bunch, Kirtikar Shukla, Pierre Triozzi, Cristina M Furdui, Wei Zhang, Mercedes Porosnicu
Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell cancer. Therapeutic advances in medical oncology 16 (2024)
Binbin Zheng-Lin, Tanios S Bekaii-Saab
Treatment options for HER2-expressing colorectal cancer: updates and recent approvals. Therapeutic advances in medical oncology 16 (2024)
Edmund Chiong, Marniza Saad, Agus Rizal A H Hamid, Annielyn Beryl Ong-Cornel, Bannakij Lojanapiwat, Choosak Pripatnanont, Dennis Serrano, Jaime Songco, Loh Chit Sin, Lukman Hakim, Matthew Chin Heng Chua, Nguyen Phuc Nguyen, Pham Cam Phuong, Ravi Sekhar Patnaik, Rainy Umbas, Ravindran Kanesvaran
Prostate cancer management in Southeast Asian countries: a survey of clinical practice patterns. Therapeutic advances in medical oncology 16 (2024)
Hong Yuan, Fei Xu, Shengzhou Wang, Di Liu, Huan Zhang, Jun Zhang, Min Shi, Chao Yan, Zhenggang Zhu
Analysis of circulating tumor DNA identifies distinct therapeutic response to intraperitoneal and intravenous paclitaxel plus S-1 in gastric cancer patients with peritoneal metastasis. Therapeutic advances in medical oncology 16 (2024)
Zi-Yao Huang, Lei Wen, Liu-Fang Ye, Yu-Ting Lu, William Pat Fong, Ren-Jing Zhang, Si-Xian Wu, Zhi-Gang Chen, Yan-Yu Cai, Rui-Hua Xu, Yu-Hong Li, Zi-Ming Du, De-Sheng Wang
Clinical and molecular characteristics of RNF43 mutations as promising prognostic biomarkers in colorectal cancer. Therapeutic advances in medical oncology 16 (2024)
Saram Zafar, Rabbia Shehzadi, Hina Dawood, Moeez Maqbool, Azza Sarfraz, Zouina Sarfraz
Current evidence of PD-1 and PD-L1 immune checkpoint inhibitors for esophageal cancer: an updated meta-analysis and synthesis of ongoing clinical trials. Therapeutic advances in medical oncology 16 (2024)
Baptiste Cervantes, Thierry André, Romain Cohen
Deficient mismatch repair/microsatellite unstable colorectal cancer: therapeutic advances and questions. Therapeutic advances in medical oncology 16 (2024)
István Farkas, Gábor Sipka, Annamária Bakos, Anikó Maráz, Zoltán Bajory, Zsófia Mikó, Tamás Czékus, Szabolcs Urbán, Linda Varga, László Pávics, Zsuzsanna Besenyi
Diagnostic value of [ 99m Tc]Tc-PSMA-I&S-SPECT/CT for the primary staging and restaging of prostate cancer. Therapeutic advances in medical oncology 16 (2024)
Zi-Yao Huang, Lei Wen, Liu-Fang Ye, Yu-Ting Lu, William Pat Fong, Ren-Jing Zhang, Si-Xian Wu, Zhi-Gang Chen, Yan-Yu Cai, Rui-Hua Xu, Yu-Hong Li, Zi-Ming Du, De-Sheng Wang
Clinical and molecular characteristics of RNF43 mutations as promising prognostic biomarkers in colorectal cancer. Therapeutic advances in medical oncology 16 (2024)
Saram Zafar, Rabbia Shehzadi, Hina Dawood, Moeez Maqbool, Azza Sarfraz, Zouina Sarfraz
Current evidence of PD-1 and PD-L1 immune checkpoint inhibitors for esophageal cancer: an updated meta-analysis and synthesis of ongoing clinical trials. Therapeutic advances in medical oncology 16 (2024)
Qianming Bai, Xiaohua Shi, Xiao-Yan Zhou, Zhiyong Liang, Shun Lu, Yilong Wu
Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer. Therapeutic advances in medical oncology 16 (2024)
Pei Yuan, Xuemin Xue, Tian Qiu, Jianming Ying
MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature. Therapeutic advances in medical oncology 16 (2024)
Jeng-Sen Tseng, Jeng-Sen Tseng, Zhe-Rong Zheng, Cheng-Hsiang Chu, Kun-Chieh Chen, Mong-Wei Lin, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Tsung-Ying Yang, Sung-Liang Yu, Jin-Shing Chen, Chao-Chi Ho, Gee-Chen Chang
Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR -mutant lung adenocarcinoma treated with first-line osimertinib. Therapeutic advances in medical oncology 16 (2024)
Jian Pan, Tingwei Zhang, Shouzhen Chen, Ting Bu, Jinou Zhao, Xudong Ni, Benkang Shi, Hualei Gan, Yu Wei, Qifeng Wang, Beihe Wang, Junlong Wu, Shaoli Song, Feng Wang, Chang Liu, Dingwei Ye, Yao Zhu
Nomogram to predict the presence of PSMA-negative but FDG-positive lesion in castration-resistant prostate cancer: a multicenter cohort study. Therapeutic advances in medical oncology 16 (2024)
Binbin Zheng-Lin, Tanios S Bekaii-Saab
Treatment options for HER2-expressing colorectal cancer: updates and recent approvals. Therapeutic advances in medical oncology 16 (2024)
Teng Ma, Changgen Liu, Tianyi Ma, Xinyi Sun, Jian Cui, Lulu Wang, Yan Mao, Haibo Wang
The impact of the HER2-low status on conditional survival in patients with breast cancer. Therapeutic advances in medical oncology 16 (2024)
Nithya Krishnamurthy, Daisuke Nishizaki, Scott M Lippman, Hirotaka Miyashita, Mary K Nesline, Sarabjot Pabla, Jeffrey M Conroy, Paul DePietro, Shumei Kato, Razelle Kurzrock
High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome. Therapeutic advances in medical oncology 16 (2024)
Junli Xue, Liqiong Xue, Wenbo Tang, Xiaoxiao Ge, Wei Zhao, Qun Li, Wei Peng, Congqi Dai, Ye Guo, Jin Li
TQB2450 in patients with advanced malignant tumors: results from a phase I dose-escalation and expansion study. Therapeutic advances in medical oncology 16 (2024)
Nithya Krishnamurthy, Daisuke Nishizaki, Scott M Lippman, Hirotaka Miyashita, Mary K Nesline, Sarabjot Pabla, Jeffrey M Conroy, Paul DePietro, Shumei Kato, Razelle Kurzrock
High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome. Therapeutic advances in medical oncology 16 (2024)
Jeng-Sen Tseng, Jeng-Sen Tseng, Zhe-Rong Zheng, Cheng-Hsiang Chu, Kun-Chieh Chen, Mong-Wei Lin, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Tsung-Ying Yang, Sung-Liang Yu, Jin-Shing Chen, Chao-Chi Ho, Gee-Chen Chang
Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR -mutant lung adenocarcinoma treated with first-line osimertinib. Therapeutic advances in medical oncology 16 (2024)